HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Suzuki, T. Articles by Narabayashi, H. Search for Related Content PubMed PubMed Citation Articles by Suzuki, T. Articles by Narabayashi, H.

Treatment of parkinsonism with L-thereo-3, 4-dihydroxyphenylserine

A pharmacokinetic study

From The Third Department of Internal Medicine, Osaka University Hospital, Osaka (Drs. Suzuki, Sakoda, Ueji, and Kishimoto), Osaka Medical Center and Research Institute for Maternal and Child Health (Dr. Hayashi), and the Department of Neurology, Juntendo University Hospital, Tokyo (Drs. Kondo and Narabayashi), Japan.

We have examined the kinetics of oral L-threo-3,4-dihydroxyphenylserine (DOPS) alone and combined with peripheral decarboxylase inhibitors in patients with Parkinson's disease and other degenerative diseases of the brain. Combined administration of L-threo-DOPS and carbidopa or benserazide produced higher plasma concentrations of L-threo-DOPS and suppressed the increase in plasma norepinephrine. This finding indicates some advantages of combined therapy with L-threo-DOPS and decarboxylase inhibitors. Measurable quantities of DL-threo- DOPS were found in the CSF during repeated administration, but there was no consistent change in norepinephrine concentration.

Address correspondence and reprint requests to Dr. Suzuki, The Third Department of Internal Medicine, Osaka University Hospital, Fukushima-ku, Osaka 553, Japan.

Presented in part at the Thirtieth Annual Conference on Mass Spectrometry and Allied Topics, Honolulu, HI, June 6-11,1982.

Accepted for publication March 8, 1984.

This article has been cited by other articles:

				M Ueda, M Hamamoto, H Nagayama, S Okubo, S Amemiya, and Y Katayama Biochemical alterations during medication withdrawal in Parkinson's disease with and without neuroleptic malignant-like syndrome J. Neurol. Neurosurg. Psychiatry, July 1, 2001; 71(1): 111 - 113. [Abstract] [Full Text] [PDF]

				M. Ueda, M. Hamamoto, H. Nagayama, K. Otsubo, C. Nito, T. Miyazaki, A. Terashi, and Y. Katayama Susceptibility to neuroleptic malignant syndrome in Parkinson's disease Neurology, March 1, 1999; 52(4): 777 - 777. [Abstract] [Full Text] [PDF]